Common use of Invoices and Payment Terms Clause in Contracts

Invoices and Payment Terms. Prior to payment by Aventis of the payments due under this Agreement, ImmunoGen must submit an invoice to Aventis which shall reference the applicable purchase order number (each, an “Invoice”). ImmunoGen shall generate Invoices for all fees and cost reimbursements. Invoices for Service Fees and for cost reimbursements shall be generated quarterly and provided to Aventis promptly after the end of the Calendar Quarter in which the fees were incurred; invoices for the milestone-based fee described above will be generated any time after Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended completion of the milestone (as completion is determined under the Project Plan and Section 8.4.7(c)). Each Invoice shall be addressed to: sanofi-aventis U.S. LLC Attention: Accounts Payable Department 1041 Xxxxx 000-000 X.X. Xxx 0000 Xxxxxxxxxxx, XX 00000-0000. Invoices for cost reimbursement shall include appropriate reasonable documentation of costs incurred; Invoices for Service Fees shall detail the personnel providing Services and the number of FTEs/hours spent in performing Services, as calculated in accordance with Section 8.4.7(a), during the quarter for which the Invoice applies. Aventis shall pay Invoices within [***] after receipt of each Invoice . Receipt or acceptance by Aventis of any Invoices under this Agreement will not preclude Aventis from questioning the correctness of the underlying information at a later date, or from exercising its rights under Section 8.4.7. If any [***] inconsistencies or mistakes are discovered in an Invoice, the Parties shall make immediate adjustment, by reimbursement or credit, as applicable. Invoices that remain unpaid more than [***] beyond the scheduled payment due date may be subject to an interest charge equal to [***], calculated from the scheduled payment due date forward; provided that in no event shall such annual rate exceed the maximum interest rate permitted by law in regard to such payments. Such payments when made shall be accompanied by all interest so accrued. All payments shall be made by wire transfer of immediately available funds to the following account: [***] ABA (routing): [***] F/C Client Funds [***] Account: [***] Account Title: ImmunoGen, Inc.

Invoices and Payment Terms. Prior to payment by Aventis of the payments due under this Agreement, ImmunoGen must submit an invoice to Aventis which shall reference the applicable purchase order number (each, an “Invoice”). ImmunoGen shall generate Invoices for all fees and cost reimbursements. Invoices for Service Fees and for cost reimbursements shall be generated quarterly and provided to Aventis promptly after the end of the Calendar Quarter in which the fees were incurred; invoices for the milestone-based fee described above will be generated any time after Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended completion of the milestone (as completion is determined under the Project Plan and Section 8.4.7(c)). Each Invoice shall be addressed to: sanofi-aventis U.S. LLC Attention: Accounts Payable Department 1041 Xxxxx 000-000 X.X. Xxx 0000 Xxxxxxxxxxx, XX 00000-0000. Invoices for cost reimbursement shall include appropriate reasonable documentation of costs incurred; Invoices for Service Fees shall detail the personnel providing Services and the number of FTEs/hours spent in performing Services, as calculated in accordance with Section 8.4.7(a), during the quarter for which the Invoice applies. Aventis shall pay Invoices within [***] thirty (30) days after receipt of each Invoice . Receipt or acceptance by Aventis of any Invoices under this Agreement will not preclude Aventis from questioning the correctness of the underlying information at a later date, or from exercising its rights under Section 8.4.7. If any [***] undisputed inconsistencies or mistakes are discovered in an Invoice, the Parties shall make immediate adjustment, by reimbursement or credit, as applicable. Invoices that remain unpaid more than [***] thirty (30) days beyond the scheduled payment due date may be subject to an interest charge equal to [***]one percent (1%) per month (twelve percent (12%) per annum), calculated from the scheduled payment due date forward; provided that in no event shall such annual rate exceed the maximum interest rate permitted by law in regard to such payments. Such payments when made shall be accompanied by all interest so accrued. All payments shall be made by wire transfer of immediately available funds to the following account: [***] Investor’s Bank & Trust Co. ABA (routing): [***] 000000000 F/C Client Funds [***] # 569530395 Account: [***] 020208420015 Account Title: ImmunoGen, Inc.

Invoices and Payment Terms. Prior to payment by Aventis of the payments due under this Agreement, ImmunoGen must submit an invoice to Aventis which shall reference the applicable purchase order number (each, an “Invoice”). ImmunoGen shall generate Invoices for all fees and cost reimbursements. Invoices for Service Fees and for cost reimbursements shall be generated quarterly and provided to Aventis promptly after the end of the Calendar Quarter in which the Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. fees were incurred; invoices for the milestone-based fee described above will be generated any time after Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended completion of the milestone (as completion is determined under the Project Plan and Section 8.4.7(c)). Each Invoice shall be addressed to: sanofi-aventis U.S. LLC Attention: Accounts Payable Department 1041 Xxxxx 000-000 X.X. Xxx 0000 Xxxxxxxxxxx, XX 00000-0000. Invoices for cost reimbursement shall include appropriate reasonable documentation of costs incurred; Invoices for Service Fees shall detail the personnel providing Services and the number of FTEs/hours spent in performing Services, as calculated in accordance with Section 8.4.7(a), during the quarter for which the Invoice applies. Aventis shall pay Invoices within [***] after receipt of each Invoice . Receipt or acceptance by Aventis of any Invoices under this Agreement will not preclude Aventis from questioning the correctness of the underlying information at a later date, or from exercising its rights under Section 8.4.7. If any [***] inconsistencies or mistakes are discovered in an Invoice, the Parties shall make immediate adjustment, by reimbursement or credit, as applicable. Invoices that remain unpaid more than [***] beyond the scheduled payment due date may be subject to an interest charge equal to [***], calculated from the scheduled payment due date forward; provided that in no event shall such annual rate exceed the maximum interest rate permitted by law in regard to such payments. Such payments when made shall be accompanied by all interest so accrued. All payments shall be made by wire transfer of immediately available funds to the following account: [***] ABA (routing): [***] F/C Client Funds [***] Account: [***] Account Title: ImmunoGen, Inc.

Invoices and Payment Terms. Prior to payment by Aventis of the payments due under this Agreement, ImmunoGen must submit an invoice to Aventis which shall reference the applicable purchase order number (each, an “Invoice”). ImmunoGen shall generate Invoices invoices for all fees and cost reimbursements. Invoices for Service Services Fees and for cost reimbursements shall must be generated quarterly monthly and provided to Aventis Genentech promptly after the end of the Calendar Quarter month in which the fees were incurred; invoices for the milestone-based fee described above will fees may be generated any time after Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended completion of the milestone (as completion is determined under the Project Plan Document and Section 8.4.7(c3.2)). Each Invoice shall be addressed to: sanofi-aventis U.S. LLC Attention: Accounts Payable Department 1041 Xxxxx 000-000 X.X. Xxx 0000 Xxxxxxxxxxx, XX 00000-0000. Invoices for cost reimbursement shall must include appropriate reasonable documentation of costs incurred; Invoices invoices for Service Services Fees shall must detail the personnel providing [***] [***] Services and the number of FTEs/hours spent in performing Services, as calculated in accordance with Section 8.4.7(a)3.1, during the quarter month for which the Invoice invoice applies; and invoices for milestone-based fees must identify the milestone completed. Aventis Genentech shall pay Invoices [***] invoices within [***] ([***]) days after receipt of each Invoice invoice or a facsimile copy of each invoice. Receipt or acceptance by Aventis Genentech of any Invoices invoices under this Agreement does not and will not preclude Aventis Genentech from questioning the correctness of the underlying information at a later date, or from exercising its rights under Section 8.4.73.5. If any [***] inconsistencies or mistakes are discovered in an Invoiceinvoice, the Parties shall make immediate adjustment, by reimbursement or credit, as applicable. Invoices that remain unpaid more than [***] ([***]) days beyond the scheduled payment due date may be subject to an interest charge equal to [***]one percent (1%) per month (twelve percent (12%) per annum), calculated from the scheduled payment due date forward; provided that in no event shall such annual rate exceed the maximum interest rate permitted by law in regard to such payments. Such payments when made shall be accompanied by all interest so accrued. All payments shall be made by wire transfer of immediately available funds to the following account: [***] Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. ABA (routing): [***] F/C Client Funds # [***] Account: [***] Account Title: ImmunoGen, Inc.